Prolastin c 1,000 MG/20 ML VLS
Ended Awarded
- Contract number
- SPE2DR26FQLL1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,084
Award facts
- Contract value 100% obligated
- $18,084.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,084.06 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract, designated as delivery order 4570062658, carries an ultimate completion date of December 9, 2025, and was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion master vehicle awarded on November 13, 2025, that establishes the company as a critical pharmaceutical supplier for Department of Defense healthcare operations worldwide through December 31, 2036.
DMS Pharmaceutical Group Inc., registered with the System for Award Management since 2001, specializes in distributing comprehensive pharmaceutical products and medical consumables to federal agencies, with a robust product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical devices. The PPV-G GEN V contract represents part of the broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply chains across military healthcare facilities globally, with DMS Pharmaceutical serving as one of multiple regional prime vendor contractors. The contractor has demonstrated substantial federal contracting activity through numerous delivery orders issued by the DLA's Medical Supply Chain division, establishing its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQLL1?
SPE2DR26FQLL1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FQLL1 worth?
The government has obligated $18,084 on SPE2DR26FQLL1.
Is contract SPE2DR26FQLL1 an order under another contract?
Yes. SPE2DR26FQLL1 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLL1 competed?
The extent of competition for SPE2DR26FQLL1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award